Anastrozole Tablet
Product Images NDC 76420-004

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 76420-004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle (Anastrozole 1mg Label)

Packaging labels for Anastrozole Tablets, USP 1 mg, an oral tablet manufactured for Accord Healthcare, Inc. and packaged by Enovachem Pharmaceuticals. The image shows multiple labels with quantities of 20, 30, 120, and 150 tablets, each label including NDC numbers, storage instructions, and standard cautionary information about prescription and storage temperature.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A Kaplan-Meier survival curve graph showing disease-free survival over time in months for two randomized treatments: anastrozole (dashed line) and tamoxifen (solid line). The y-axis represents the proportion of patients alive and disease-free, ranging from 0 to 1.0. Patient numbers at risk for each group at various time points are listed below the x-axis.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve chart comparing disease-free survival in months between two randomized treatments: anastrozole and tamoxifen. The y-axis shows the proportion alive and disease-free, and the x-axis shows time in months up to 96. A patient number table at risk over time is displayed below the graph for both treatments.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier survival curve chart comparing the proportion of patients event-free over time up to 120 months for two treatments: Anastrozole and Tamoxifen. The x-axis represents time to event in months, and the y-axis shows the proportion event-free. The chart includes the number of patients at risk at various time points for both treatments.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

Kaplan-Meier survival curve chart showing the proportion of patients remaining event-free over time in months up to 120 months. It compares two randomized treatments, Anastrozole and Tamoxifen, with the number of patients at risk displayed below the time axis. The vertical axis represents the proportion event-free, ranging from 0.50 to 1.00.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A Kaplan-Meier curve chart comparing the proportion of patients not progressing over time (months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion of patients without disease progression. The chart includes the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A Kaplan-Meier survival curve graph showing the proportion not progressed over time (months) for two treatments: Anastrozole and Tamoxifen. The X-axis represents time to progression in months, and the Y-axis shows the proportion not progressed. The graph compares these two randomized treatments in a clinical context.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure diagram of the active ingredient Anastrozole. The image shows the molecular framework of Anastrozole including aromatic rings and nitrile groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.